Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Real-time OTC Markets

More quotes

Market Closed - OTC Markets 12:39:50 2025-12-24 EST			5-day change	1st Jan Change
0.000100 ^USD	-80.00%		-.--%	-80.00%

23-12-14	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	CI
23-12-11	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	CI

Market Cap	1.17M 1.04M 961K 871K 1.63M 111M 1.66M 11.46M 4.6M 58.26M 4.38M 4.28M 184M	P/E 2021	-2.63x	P/E 2022	-1.23x
Enterprise Value	4.36M 3.91M 3.6M 3.26M 6.09M 414M 6.2M 42.88M 17.21M 218M 16.38M 16.03M 687M	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

23-12-14	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	CI
23-12-11	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	CI
23-12-11	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	CI
23-11-21	Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	CI
23-11-21	Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	CI
23-11-21	Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	CI
23-11-09	Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-10-18	TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	MT
23-10-17	Top Midday Decliners	MT
23-10-17	Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	MT
23-10-17	Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	CI
23-10-10	Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	MT
23-08-14	Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

23-10-18	TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	MT
23-07-26	Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating	MT
22-11-16	Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5	MT
22-09-09	Morgan Stanley Adjusts Price Target on Evelo Biosciences to $4 From $5, Keeps Equalweight Rating	MT
22-09-09	Morgan Stanley Cuts Price Target on Evelo Biosciences to $4 From $5, Maintains Equalweight Rating	MT

Evelo Biosciences, Inc. Stock

Stocks

EVLO

US2997342025

Biotechnology & Medical Research

Valuation: Evelo Biosciences, Inc.

Chart: Evelo Biosciences, Inc.

Latest news: Evelo Biosciences, Inc.

Analysts' recommendations: Evelo Biosciences, Inc.

Press Releases: Evelo Biosciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Evelo Biosciences, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

23-10-17	Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	AQ
23-08-14	Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights	AQ
23-07-12	Evelo Biosciences Closes $25.5 Million Private Placement	AQ
23-07-10	Evelo Biosciences Announces $25.5 Million Private Placement	AQ
23-06-29	Evelo Biosciences Announces Reverse Stock Split Effective	AQ

1 day	-80.00%
3 months	-66.67%
6 months	-60.00%
Current year	-80.00%

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.76
5 years	0		254.8
10 years	0		398.57

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/7/23	Ann Thorell	Exercice	Chief Financial Officer	14,811	0.0786%
11/7/23	Simba Gill	Exercice	Chief Executive Officer	2,516	0.0134%
11/7/23	Mark Bodmer	Exercice	Chief Technology Officer	16,413	0.0871%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVELO BIOSCIENCES, INC.	-80.00%	-.--%	-80.00%	-99.98%	1.9K
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	64.38B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.16B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.16B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	45.33B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.25B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	40.78B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	33.8B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-2.88%	+21.60%	-11.92%	23.57B
Average	-7.91%	+4.25%	+41.44%	+137.20%	39.27B
Weighted average by Cap.	+0.02%	+3.64%	+52.31%	+161.99%

	2021	2022
Net sales	-	-
Net income	-122M -109M -101M -91.2M -170M -11.6B -174M -1.2B -482M -6.1B -459M -449M -19.24B	-115M -103M -94.35M -85.49M -160M -10.87B -163M -1.13B -452M -5.72B -430M -421M -18.04B
Net Debt	-12.15M -10.88M -10.01M -9.07M -16.95M -1.15B -17.27M -119M -47.91M -607M -45.59M -44.62M -1.91B	3.2M 2.86M 2.63M 2.39M 4.46M 304M 4.55M 31.42M 12.61M 160M 12M 11.75M 504M